A Phase I Study of ICP-022 in Healthy Subjects
Phase 1
Completed
- Conditions
- Systemic Lupus ErythematosusRheumatoid Arthritis
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Innocare Pharma Australia Pty Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT03189017
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath